By Reuters

(Reuters) -Pfizer (PFE.N) said on Monday it would acquire weight-loss drug developer Metsera (MTSR.O) for up to $4.9 billion to secure its position in the lucrative obesity treatment market.

Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar

This week on Reuters

• US equity funds record biggest weekly outflow in five weeks

• BOJ signals final phase of Ueda's stimulus unwind - selling ETFs

• Trump Media and Technology seeks SEC approval for five new ETFs